Seeking Emerging MoAs, Biologics & Delivery Innovations Whilst Navigating Regulatory Access & Pricing Challenges in Europe
Returning to Amsterdam this May, the 7th Dermatology Drug Development Summit Europe arrives at a defining moment for the field. As dermatology pipelines mature rapidly into Phase II–III, gene therapies reach approval, and immuno-dermatology mechanisms such as JAK, TYK2, IL and OX40 reshape competitive landscapes, the focus has decisively shifted toward clinical execution, regulatory readiness, and European access.
What’s new for 2026 is both the depth and breadth of industry representation. This year’s programme brings together a broader range of senior pharma voices than ever before, including Sanofi, Glenmark Pharmaceuticals, Pierre Fabre, Merck and Boehringer Ingelheim, alongside innovative biotechs navigating late-stage development and partnering.
Together, they will share candid insights on generating robust clinical signals in high-placebo indications, designing feasible European trials, navigating payer and HTA scrutiny, and translating emerging modalities into approvable, accessible dermatology medicines.
With 60+ senior clinical, medical and regulatory leaders in an intimate, single-track setting, the summit is designed for meaningful exchange rather than passive listening, enabling attendees to benchmark strategy, pressure-test assumptions, and build partnerships that accelerate real-world impact across common and rare dermatological conditions.
Diverse participants (KOL, CRO, Pharma industry), detailed deep dive into some key derm indications, good overview about the future trends in key therapies.
Jiri Havranek, Senior Vice President - Business Development & Emerging Markets, Glenmark Pharmaceuticals
Good relevant topics for me, with several good novel approached targeting some of dermatology indications and good meeting to interacting easily with people in academia and Drug development with almost similar development/research interest.
Ehsanollah Esfandiari, Global Head of Development Project Strategy & Clinical Sciences, Kyowa Kirin
The intimate and transparent atmosphere, the dedicated networking sessions, the relevance and quality of the presentations and the number of dermatology leaders attending.
Sofie Arpe, Clinical Partnership & Dermatology Lead, Sanos Group
Explore the Full Events Guide
- 18 World Class Speakers
- 2 Deep Dive Pre-Conference Workshops
- 60+ Attendees from Pharma & Biotech
- 6+ Hours of Networking Time Available
- 3 Days of Clinical & Commercial Conversations
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda to Discover the Clinical & Access Priorities Shaping Dermatology R&D in 2026
Explore a focused agenda of late-stage case studies, interactive workshops and peer-led discussions tackling clinical design, regulatory access, reimbursement and differentiated dermatology modalities.
Partner to Position Your Solutions at the Centre of Active Dermatology Pipelines
Partner with the summit to showcase your capabilities to senior pharma and biotech teams actively seeking support across biomarkers, imaging, clinical trials, manufacturing and formulation.
Join Biopharma Experts to Connect with the Decision-Makers Driving Dermatology Development Forward
Join 60+ senior leaders from pharma and biotech for high-value networking, candid peer exchange and relationship-building across late-stage development, access and launch in Europe.